Kenvue Shares Lag Nasdaq Amid Tylenol Litigation and Margin Pressure

Kenvue Inc. shares have slipped 11.7% from their 52-week high of $20.13, a level reached on July 7, 2026. The Summit, New Jersey-based consumer health company now trails the broader market, with the Nasdaq Composite gaining 2% over the past three months while KVUE stock declined by 1.6%. According to GN stocks/nasdaq data, this divergence highlights specific operational headwinds affecting the large-cap firm, which maintains a market capitalization of approximately $34.1 billion.

Over the past 52 weeks, Kenvue shares have fallen 5.7%, a significant underperformance compared to the Nasdaq Composite's 19.5% return in the same period. Year-to-date, KVUE has gained 3.1%, lagging behind the index's 13.3% growth. Technical indicators confirm this downward trajectory, as the stock has remained below its 50-day moving average since late August and recently dropped below its 200-day moving average in early September.

Litigation Revives Pressure on Tylenol Brand

A primary driver of recent share weakness is renewed legal uncertainty surrounding the company's flagship Tylenol brand. On July 13, a federal appeals court revived more than 500 private lawsuits alleging a link between Tylenol use during pregnancy and autism or ADHD. This ruling immediately impacted investor sentiment, sending Kenvue shares down 1.8% in afternoon trading. The legal risk adds a layer of financial uncertainty to the company's otherwise stable consumer health portfolio.

Inflation and Tariffs Squeeze Margins

Beyond legal matters, Kenvue faces margin pressure from inflation, tariffs, and currency-related costs. These factors have eroded the profitability of its global operations, which span personal care, skincare, and oral care categories. While the company benefits from strong gross margins and a favorable international presence, these structural costs are currently offsetting gains in high-growth areas like Skin Health and Beauty. The net result is a constrained bottom line that deters investors seeking consistent earnings growth.

Competitive Landscape Reflects Sector Challenges

Kenvue is not alone in facing these headwinds, as major competitor Procter & Gamble also shows signs of weakness. Procter & Gamble shares have risen only 1.4% year-to-date and declined 8.4% over the past year, underperforming Kenvue slightly on a one-year basis but similarly lagging the broader market. This parallel performance suggests that challenges related to consumer spending power and regulatory scrutiny are affecting the entire household products sector, rather than being isolated to Kenvue's specific brand mix or geographic exposure.